Patients enrolled (n) | Median age (years) (range) | FIGO | G | hrHPV status | |

Immunohistochemical analysis | |||||

HSIL | 36 | 61.9 (27.5–89.9) | Negative n=2; Positive n=27; N/A n=7 | ||

dVIN | 13 | 68.7 (50.1–84.4) | Negative n=11; N/A n=2 | ||

Primary VSCC | 38 | 69.9 (37.3–93.2) | I n=31; II n=2; III n=5 | G1 n=16; G2 n=15; G3 n=7 | Negative n=17; Positive n=16; N/A n=5 |

recVSCC | 8 | 71.4 (58.9–83.6) | |||

ELISA test | |||||

Healthy volunteers | 16 | 45.6 (25.6–64.3) | |||

HSIL | 16 | 50.2 (26.3–58.5) | |||

dVIN | 7 | 60.5 (34.6–79.5) | |||

Primary VSCC | 36 | 72.2 (58.6–86.2) | I n=15; II n=5; III n=13; IV n=1; N/A n=2 | G1 n=11; G2 n=18; G3 n=3; N/A n=4 | Negative n=6; Positive n=13; N/A n=17 |

recVSCC | 2 | 74.8 and 85.8 |

dVIN, differentiated-type vulvar intraepithelial neoplasia; FIGO, The International Federation of Gynecology and Obstetrics; G, tumour grade; hrHPV, high-risk human papilloma virus; HSIL, high-grade squamous intraepithelial lesions; N/A, data not available; recVSCC, recurrent vulvar squamous cell carcinoma; VSCC, vulvar squamous cell carcinoma.